Penile Cancer Research

For enrollment information involving the following trial, please contact a member of our research support staff.


ECOG-InPact

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Inclusion Criteria:

  • Histologically-proven squamous cell carcinoma of the penis.

  • Stage:
    – any T, N1 (i.e. a palpable mobile unilateral inguinal lymph node), M0 or;
    – any T, N2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), M0 or;
    – any T, N3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), M0

  • Measurable disease as determined by RECIST (version 1.1) criteri.

  • Performance Status ECOG 0, 1 or 2.

Exclusion Criteria:

  • Pure verrucous carcinoma of the penis.

  • Non-squamous malignancy of the penis.

  • Squamous carcinoma of the urethra.

  • Stage M1.

  • Previous chemotherapy or chemoradiotherapy outside of the InPACT trial.

  • Concurrent malignancy (other than SCC or basal cell carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last three years.

Principal Investigator: Viraj Master, MD, PhD

Co-Investigators & Collaborators: Department of Urology: Kenneth Ogan, MD, Department of Hematology and Medical Oncology: Mehmet Bilen, MD, Bradley Carthon, MD, PhD, Omer Kucuk, MD, David Lawson, MD, Department of Radiation Oncology: Joseph Shelton, MD, Ashesh Jani, MD